Literature DB >> 12975552

5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children.

Mohsen S El-Alfy1, Mohamed M El-Tawil, Naglaa Shahein.   

Abstract

UNLABELLED: The long-term outcome after splenectomy in children with chronic immune thrombocytopenic purpura (ITP) has not been widely analyzed. We reviewed the medical records of 288 children and adolescents with chronic ITP between 1980 and 1996: 112 were splenectomized; 59 were steroid resistant and 42 were steroid dependent, and 11 were managed with repeated courses of intravenous immunoglobulin (IVIG). All had platelet counts (PCs) <30 x 10(9)/l with frequent bleeding episodes or persistent thrombocytopenia <10 x 10(9)/l. Ninety-eight patients (88%) were evaluated; 58 (60%) patients had never received immunotherapy for ITP following splenectomy. At 5 years, 44 (45%) remained in complete response (CR) and 34 (35%) in partial response (PR). In multivariate analysis, steroid-resistant patients were more likely to relapse after an initial CR (RR 5.2).
CONCLUSION: The long-term CR was 45%; 60% had stable PCs >30 x 10(9)/l not requiring therapy. Most postsplenectomy relapses occurred during the 1st year. Initial response to steroids and IVIG prior to splenectomy was a predictor of long-term response to splenectomy. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975552     DOI: 10.1159/000072409

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  Evidence-based management of immune thrombocytopenia: ASH guideline update.

Authors:  Cindy E Neunert; Nichola Cooper
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia.

Authors:  Rachael F Grace; Carolyn M Bennett; A Kim Ritchey; Michael Jeng; Courtney D Thornburg; Michele P Lambert; Michelle Neier; Michael Recht; Manjusha Kumar; Victor Blanchette; Robert J Klaassen; George R Buchanan; Margaret Heisel Kurth; Diane J Nugent; Alexis A Thompson; Kimo Stine; Leslie A Kalish; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

3.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

4.  Factors predicting long-term responses to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  Hitoshi Ojima; Toshihide Kato; Kenichirou Araki; Kaori Okamura; Ryokuhei Manda; Isao Hirayama; Yasuo Hosouchi; Yasuji Nishida; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

5.  Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012.

Authors:  Sandra Regina Loggetto; Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Wanderley Marques Bernardo; Leticia Medeiros; Andrea Thives de Carvalho Hoepers
Journal:  Rev Bras Hematol Hemoter       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.